Adapting palliative radiation therapy for ...
Document type :
Compte-rendu et recension critique d'ouvrage
PMID :
Permalink :
Title :
Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic : GEMO position paper
Author(s) :
Thureau, Sébastien [Auteur correspondant]
Equipe Quantification en Imagerie Fonctionnelle [QuantIF-LITIS]
Faivre, Jean [Auteur]
Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] [UNICANCER/ICL]
Assaker, Richard [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Biver, Emmanuel [Auteur]
Geneva University Hospital [HUG]
Université de Genève = University of Geneva [UNIGE]
Confavreux, Cyrille [Auteur]
Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS]
Debiais, Françoise [Auteur]
Service de rhumatologie [Poitiers]
Duterque-Coquillaud, Martine [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Giammarile, Fransesco [Auteur]
Centre Léon Bérard [Lyon]
Heymann, Dominique [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Lecouvet, Frédéric [Auteur]
Institut de Recherche Expérimentale et Clinique [IREC]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
Morardet, Laetitia [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Paycha, Frederic [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Body, Jean-Jacques [Auteur]
Centre Hospitalier Universitaire Brugmann [Bruxelles] [CHU]
Vieillard, Marie-Hélène [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Equipe Quantification en Imagerie Fonctionnelle [QuantIF-LITIS]
Faivre, Jean [Auteur]
Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] [UNICANCER/ICL]
Assaker, Richard [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Biver, Emmanuel [Auteur]
Geneva University Hospital [HUG]
Université de Genève = University of Geneva [UNIGE]
Confavreux, Cyrille [Auteur]
Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS]
Debiais, Françoise [Auteur]
Service de rhumatologie [Poitiers]
Duterque-Coquillaud, Martine [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Giammarile, Fransesco [Auteur]
Centre Léon Bérard [Lyon]
Heymann, Dominique [Auteur]
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Lecouvet, Frédéric [Auteur]
Institut de Recherche Expérimentale et Clinique [IREC]
Université Catholique de Louvain = Catholic University of Louvain [UCL]
Morardet, Laetitia [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Paycha, Frederic [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Body, Jean-Jacques [Auteur]
Centre Hospitalier Universitaire Brugmann [Bruxelles] [CHU]
Vieillard, Marie-Hélène [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Journal title :
Journal of Bone Oncology
Pages :
100291
Publisher :
Amsterdam : Elsevier, c2012-
Publication date :
2020-04-13
ISSN :
2212-1374
HAL domain(s) :
Sciences du Vivant [q-bio]/Biologie cellulaire/Interactions cellulaires [q-bio.CB]
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Anatomie, Histologie, Anatomopathologie [q-bio.TO]
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Rhumatologie et système ostéo-articulaire
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Pédiatrie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Endocrinologie et métabolisme
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Anatomie, Histologie, Anatomopathologie [q-bio.TO]
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Rhumatologie et système ostéo-articulaire
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Pédiatrie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Endocrinologie et métabolisme
Sciences du Vivant [q-bio]/Cancer
English abstract : [en]
The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe ...
Show more >The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.Show less >
Show more >The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.Show less >
Language :
Anglais
Popular science :
Non
Source :
Submission date :
2024-02-17T04:21:08Z
Files
- document
- Open access
- Access the document
- 1-s2.0-S2212137420300464-main.pdf
- Open access
- Access the document